African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma brucei spp., is responsible for ,30,000 deaths each year. Available treatments for this disease are poor, with unacceptable efficacy and safety profiles, particularly in the late stage of the disease when the parasite has infected the central nervous system. Here we report the validation of a molecular target and the discovery of associated lead compounds with the potential to address this lack of suitable treatments. Inhibition of this target-T. brucei N-myristoyltransferase-leads to rapid killing of trypanosomes both in vitro and in vivo and cures trypanosomiasis in mice. These high-affinity inhibitors bind into the peptide substrate pocket of the enzyme and inhibit protein N-myristoylation in trypanosomes. The compounds identified have promising pharmaceutical properties and represent an opportunity to develop oral drugs to treat this devastating disease. Our studies validate T. brucei N-myristoyltransferase as a promising therapeutic target for human African trypanosomiasis.
Protein N-myristoylation is a ubiquitous eukaryotic co-and posttranslational modification and is required for the membrane targeting and biological activity of many important proteins 1, 2 . The N-myristoylation reaction-the transfer of C 14:0 myristic acid from myristoyl-coenzyme A (CoA) to the amino group of amino-terminal glycine residues within specific sequence contexts 3 -is catalysed by the enzyme myristoyl-CoA-protein N-myristoyltransferase (NMT; International Union of Biochemistry and Molecular Biology accession EC 2.3.1.97) 4 . In T. brucei, NMT activity is encoded by a single gene, which has been shown to be essential for parasite growth using RNA interference 5 . The effects of NMT knockdown on T. brucei are probably complex as more than 60 proteins are predicted to be N-myristoylated in this organism 6 . Experimentally validated targets for NMT include ADP ribosylation factors (ARF) 7 , ADP ribosylationlike factors (ARL) 8 , a calpain-type protease (CAP5.5, systematic gene name Tb927.4.3950) 9 and, in the related Leishmania major and T. cruzi parasites, hydrophilic acylated surface proteins 10 and flagellar calcium-binding protein 11 , respectively. The predicted pleiotropic effects of NMT inhibition on trypanosome physiology make it an attractive target for therapeutic intervention. NMT has also been considered as an anticancer 12 , antifungal 13 and antiviral 14 target. Fungal NMT orthologues have been shown to be druggable, although broadspectrum activity has not been achieved. Nevertheless, because there is good evidence from these programmes that selectivity over human NMT is possible, NMT has been proposed as a target for the treatment of human African trypanosomiasis and other parasitic diseases 15, 16 . There are two human isozymes sharing 77% identity (HsNMT1 and HsNMT2) 17 of which HsNMT2 is the closest human homologue to T. brucei NMT (TbNMT), with overall 55% identity and 69% similarity. On the basis of 31 residues that are within 5 Å of DDD85646 in the active site, this rises to 83% identity and 90% similarity.
Pyrazole sulphonamide inhibitors of TbNMT So far, no drug-like, potent inhibitors of TbNMT have been reported 18 . Screening of a 62,000 diversity-based compound library 19 against TbNMT identified a number of 'lead-like' hits, including a chemically tractable series with moderate potency (2 mM) based on a pyrazole sulphonamide scaffold (DDD64558). Optimization of the screening hit, involving the design and synthesis of over 200 compounds, identified highly potent inhibitors of TbNMT with singledigit nanomolar half-maximum inhibitory concentration (IC 50 ) values and levels of selectivity over human NMT enzymes in the 1-to .100-fold range (Fig. 1a ). The relative lack of activity of the piperidine analogue (DDD85635) of DDD85602 indicated that the terminal basic nitrogen of DDD85602 was crucial for activity. The series was optimized by rigidifying the flexible linker to the amine moiety of DDD85602 and by adding the chlorines observed to give an increase in activity in the unelaborated template (DDD73234). TbNMT inhibitors so obtained (for example, DDD85646) inhibited the proliferation of bloodstream form T. brucei in culture with the best compounds yielding half-maximum effective concentration (EC 50 ) values between 0.8 and 3 nM and clear windows of selectivity (.200-fold) with respect to proliferation of a prototypical mammalian cell type (MRC5). We attribute the increased selectivity at the cellular level to differences in cell biology between host and parasite, although differential cellular pharmacokinetic behaviour has not been definitively ruled out. Critically, a tight correlation (r 2 5 0.875) was observed between IC 50 and EC 50 values for TbNMT and T. brucei proliferation, respectively, over a 10,000-fold potency range ( Fig. 1b) ; this indicates that inhibition of TbNMT was driving the observed antiparasitic effect of these compounds. The poorer correlation for the most potent compounds ( Fig. 1b , lower left) is probably due to the limit of the enzyme assay to provide accurate IC 50 determinations for such highly active, tight-binding inhibitors (see Supplementary Fig. 1 ). As a result of its impressive potency in inhibiting both TbNMT and T. brucei proliferation in vitro, together with its promising physicochemical properties, DDD85646 was assessed for efficacy in animal models of trypanosomiasis.
TbNMT inhibitor cures acute trypanosomiasis in vivo DDD85646 is moderately bioavailable (approximately 20%) and demonstrates good exposure after oral dosing at 10 and 50 mg kg 21 to female NMRI mice, with the free drug level above the effective concentration calculated to achieve 99% inhibition of parasite growth (EC 99 ) for T. brucei brucei (T. b. brucei) proliferation for over 6 and 10 h, respectively ( Fig. 2a ). Furthermore, this compound cured all animals in the T. b. brucei acute mouse model of human African trypanosomiasis at a minimal oral dose of 12.5 mg kg 21 (twice a day for 4 days) ( Fig. 2b ). Cure of all animals was also obtained with shorter oral dosing schedules: 100 mg kg 21 twice a day for 1 day and 25 mg kg 21 twice a day for 2 days. Notably, DDD85646 also cured all animals at 50 mg kg 21 (twice a day for 2 days) in the more refractory but clinically relevant T. b. rhodesiense model of human African trypanosomiasis (see Supplementary Fig. 2 ). This reduced sensitivity in vivo is not due to reduced sensitivity to the compound in vitro (T. b. rhodesiense, EC 50 0.6 nM), but may be a result of the known precedent for this species to occupy privileged sites in vivo. Notably, the efficacy observed for DDD85646 was comparable to the responses observed for the clinically used drugs pentamidine and melarsoprol in the T. b. brucei model (minimal full cure doses were 1 mg kg 21 and 0.5 mg kg 21 (intraperitoneal), respectively). Furthermore, despite the minimal window of in vitro enzyme selectivity between TbNMT and mammalian (human) NMT ( Fig. 1a and see later), this compound was well tolerated at efficacious doses.
TbNMT inhibitors are trypanocidal Addition of DDD85646 resulted in rapid killing of trypanosomes both in vivo and in vitro ( Fig. 3a, b ). Parasite counts dropped to below detectable levels within 12 h of dosing mice at 50 mg kg 21 twice a day. Addition of DDD85646 (50 nM) to bloodstream form T. brucei cultures in vitro also resulted in rapid killing with numbers of motile cells reduced to below detectable levels between 24 and 48 h. The apparent differences in the kinetics of death between the in vivo and in vitro systems are probably a combination of the harsher in vivo environment for drug-damaged trypanosomes and the fact that compound exposure reached higher concentrations in vivo (up to ,1 mM), compared with 50 nM in vitro.
The trypanocidal mechanism of compound action was confirmed by subjecting T. brucei treated in vitro with 50 nM DDD85646 to live/ dead fluorescence-activated cell sorting (FACS) analysis, which showed .95% cell death within 24 h of treatment (see Supplementary Fig. 3 ). Furthermore, wash-out experiments showed that death was irreversible after 48 h of exposure to 50 nM compound (data not shown). Microscopic examination of the trypanosomes treated with DDD85646 in vivo and in vitro showed the same abnormal morphology, that is, the development of a large vesicular structure (Fig. 3c) . A scanning electron micrograph of a treated trypanosome clearly shows the rounded and swollen features of this phenotype compared to control (Fig. 3d) . Notably, rapid cell killing with a similar morphological phenotype has been previously observed after treatment with myristate analogues, such as 10-(propoxy)decanoic acid 20 . This morphology closely resembles the 'BigEye' phenotype observed in bloodstream form T. brucei when endocytosis is disrupted by the knockdown of clathrin heavy chain, TbRAB5 21, 22 or TbARF1 7 , leading to expansion of the flagellar pocket. Parasites with enlarged flagellar pockets are clearly visible in the DDD85646-treated trypanosome population (Fig. 3e ). Additional studies are required to understand fully the cellular effects of NMT inhibition.
Inhibitor acts 'on target'
Incubation of bloodstream form T. brucei with [ 3 H]myristic acid results in the biosynthetic radiolabelling of myristoylated substrates, particularly the highly abundant variant surface glycoprotein (VSG) 23 .
Using this method, but including a detergent lysis step that activates an endogenous phospholipase C (PLC) to release the [ 3 H]myristate label from the glycosylphosphatidylinositol (GPI) anchor of VSG 24 , a number of putative N-[ 3 H]myristoylated proteins were visualized by SDS-polyacrylamide gel electrophoresis (PAGE) and fluorography (Fig. 4a, lane 2) . The labelling of most of these proteins was eliminated by prior treatment with DDD85646 (Fig. 4a, lane 1) . To confirm that most of the proteins labelled with [ 3 H]myristic acid were indeed N-myristoylated, a duplicate gel was treated with 0.2 M NaOH in methanol before fluorography to remove base-labile hydroxy-or thioester linked [ 3 H]myristate (Fig. 4a, lanes 3 and 4) . Three faint DDD85646-insensitive bands were removed (Fig. 4a, compare lanes 1 and 2 with lanes 3 and 4) ; these probably include traces of residual GPI-anchored VSG at 55 kilodalton (kDa) 24 and thioestermyristoylated GPI-PLC at 42 kDa 25 . To assess whether DDD85646 specifically inhibited N-[ 3 H]myristoylation, the same cells were labelled in parallel with [ 35 S]methionine. Pre-treatment of parasites with DD85646 had no effect on [ 35 S]methionine incorporation into proteins, showing that the compound has no effect on general protein synthesis (Fig. 4a, lanes 5 and 6) .
Further evidence that DDD85646 was acting on target in the trypanosome was obtained by overexpressing TbNMT (fivefold) in a tetracycline-inducible manner; this resulted in an eightfold reduction in DDD85646 potency against these cells (Fig. 4b ).
Another independent approach was taken using one of the few known substrates of TbNMT in T. brucei, TbARF1. This protein has a central role in endocytosis and Golgi-lysosome trafficking, where tetracycline-induced expression of a constitutively active GTP-locked mutant (Q71L) causes rapid cell death in bloodstream form T. brucei in an N-myristoylation-dependent manner 7 . Short-term treatment (5 h) with 10 nM DDD85646 rescued these TbARF1(Q71L)-expressing cells from death (Fig. 4c ), presumably by preventing N-myristoylation of newly produced TbARF1(Q71L) protein. Although the Q71L mutant protein could not be detected by western blotting, as previously reported 7 , the inducible expression of the related, but myristoylation-blocked, G2A/Q71L mutant in the presence of DDD85646 does show that its effect on cell survival was not due to interference with tetracycline induction of these mutants.
Taken together, these data provide strong evidence that DDD85646 acts to inhibit TbNMT in bloodstream form trypanosomes and that this is directly linked to inhibition of proliferation. These data also provide a potential link between inhibition of TbNMT and disruption of the function of the TbNMT substrate TbARF1, known to operate in protein trafficking and endocytic processes.
Inhibitor binds in TbNMT peptide pocket
The target product profile for a new drug to combat human African trypanosomiasis, as defined by the Drugs for Neglected Diseases initiative, requires compounds that are safe and efficacious against both the stage 1 disease, when parasites are present in the blood, lymph and interstitial fluids, and the stage 2 disease, when parasites are also present in the central nervous system (CNS). The DDD85646 compound does not yet meet these criteria and will have to be optimized for selectivity over human NMT and for diffusion into the CNS, while retaining excellent potency against TbNMT and bloodstream form T. brucei cells. To achieve these objectives, a detailed understanding of the interaction between DDD85646 and TbNMT is required. Characterization of the mode of inhibition of the early hits revealed competition with the peptide substrate as a probable mode of inhibition for the series. Thus, a shift in IC 50 from 1 to 4.3 mM for an early hit was seen when the peptide substrate concentration in the assay was increased from 0.5 to 16 mM (Fig. 5a ). Surface plasmon resonance (SPR) studies confirmed a 1:1 binding stoichiometry of DDD85646 with TbNMT ( Fig. 5b) and showed that the binding affinity of the compound was increased in the presence of myristoyl-CoA from 33 nM to 1 nM (data not shown). Accurate determination of binding affinity using SPR also showed a potential small window of selectivity between TbNMT and human NMT with binding constants of 1 and 14 nM, respectively. Owing to tight binding of this compound (see Supplementary Fig. 1 ), this selectivity was less clear in the biochemical assay, which recorded 2 and 4 nM (IC 50 ), respectively. Furthermore, this emerging selectivity is clearly driven by differing off-rates, and optimization around this parameter will not only be important in improving selectivity, but also in sustaining a high residency time of binding to TbNMT. The structure of TbNMT has yet to be solved. However, using L. major NMT (LmNMT) as a model system, the binding of DDD85646 in the peptide substrate binding site has been confirmed by X-ray crystallography (Fig. 5c , for stereo view see Supplementary Fig. 4 ). LmNMT has 74% overall sequence identity with TbNMT and 94% identity within the peptide-binding site (see Supplementary Fig. 5 ). The binding mode shows the piperazine interacting with the carboxy-terminal carboxylate of NMT by means of a tightly coordinated water molecule as opposed to a direct hydrogen bond. The sulphonamide makes water-bridged interactions with the highly conserved residue His 219 and with the backbone NH group of Gly 397. The geometry of the sulphonamide creates a significant bend in the structure, allowing the pyrazole to fit into a lipophilic pocket where it acts as a hydrogen-bond acceptor from Ser 330. The binding mode is of particular interest because all but the latter interactions are through water-mediated hydrogen bonds; a mode not readily predicted using computational techniques. Overlaying the structure of Saccharomyces cerevisiae NMT in complex with substrate peptide (Protein Data Bank accession 1IID) 26 with the LmNMT complex shows that DDD85646 occupies the peptide binding site with the basic piperazine moiety mimicking the N terminus of the substrate (see Supplementary Fig. 6 ).
Conclusions
We have presented evidence that our model TbNMT inhibitor, DDD85646, kills bloodstream form T. brucei by acting on TbNMT in situ. There are probably several downstream consequences of TbNMT inhibition in the parasite, as the enzyme has over 60 putative substrates 6 , and this no doubt explains the speed of killing and the marked morphological changes observed on treatment with this compound. The emergence of the BigEye phenotype, and the possible link to TbARF1 activity, suggests that disturbance of endocytosis is one mechanism by which TbNMT inhibitors act in bloodstream form T. brucei. Interestingly, knockdown of TbNMT levels in bloodstream form T. brucei by RNA interference to 16% of wild-type levels, although fatal in vitro and in vivo, does not lead to the BigEye phenotype but rather to the accumulation of vesicles close to the flagellar pocket 27 . It is notable that, despite the small window of selectivity between human NMT and TbNMT, DDD85646 shows promising selectivity at the cellular level. One might speculate that T. brucei cells are hypersensitive to NMT inhibition because of unique or unusual aspects of their biochemistry and/or cell biology. In this context, the extremely high endocytic rate of bloodstream form T. brucei (some 9 times faster than fibroblasts and 2.6 times faster than macrophages), combined with the entire endocytic/exocytic process occurring in the flagellar pocket, is noteworthy 28 . The parasite's requirement for this high endocytic rate relates to its need to remove antibody from the cell surface and to recycle the protective VSG coat 29 .
Finally, we may conclude that TbNMT is one of the few T. brucei proteins that has been comprehensively validated as a drug target for human African trypanosomiasis. The TbNMT inhibitors described meet many requirements for a greatly needed new therapeutic agent for human African trypanosomiasis. Further optimization of this series towards improved CNS penetration and selectivity is currently underway. In the meantime, DDD85646 will serve as an excellent chemical tool for investigation of the biology of protein N-myristoylation across a range of organisms.
METHODS SUMMARY
Enzyme activity assays were performed in scintillation proximity format 18 , with minor modifications. Proliferation assays were performed using resazurin as an indicator of metabolic activity 30 . TbNMT was immobilized onto NTA sensor chips using standard immobilization protocols and kinetics of binding of compound analysed on Biacore T-100. Details of all standard methods including compound exposure studies and efficacy studies, metabolic labelling, microscopy and crystallography can be found in Methods. Chemical synthesis details can be found in Supplementary Materials.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
